You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《藍籌業績》藥明生物(02269.HK)去年純利升100.6%至33.89億人民幣
阿思達克 03-22 20:26
藥明生物(02269.HK)公佈截至去年底止全年業績,純利升100.6%至33.89億人民幣(下同),純利率由30.2%升至34.1%,每股盈利0.81元。經調整純利升92.6%至33.16億元,經調整純利率由30.7%升至32.2%,經調整每股盈利0.79元。不派末期息。 收益升83.3%至102.9億元。集團未完成訂單總量增長20.1%至135.97億美元,其中未完成服務訂單增長19.9%至79.46億美元,而未完成潛在裏程碑付款訂單20.4%至56.51億美元。集團三年內未完成訂單總額增長98.2%至28.9億美元。截至去年底,集團爲超過470名客戶提供服務,而去年則爲369名客戶。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account